Biotechnology Jobs and AI in the UK (2026): What AI-Driven Drug Discovery Means for Biotech Careers

Artificial intelligence and automated laboratories have moved from conference slides into daily practice across the UK's life sciences cluster. For anyone weighing up biotechnology jobs in 2026, the obvious question is whether this technology is a threat or an opportunity. The honest answer, on the evidence so far, is that it appears to be reshaping roles rather than erasing them, and that the people who learn to work alongside these tools tend to be the ones in demand. This guide sets out what AI-driven drug discovery and lab automation actually mean for biotech careers in Britain, drawing on current 2025 to 2026 data.

The Short Answer

AI and lab automation are changing biotechnology jobs in the UK, but the broad picture is one of role redesign rather than wholesale replacement. Routine tasks such as data cleaning, literature triage and repetitive pipetting are increasingly automated, while demand is rising for people who can design experiments, interpret AI output and bridge biology with computation. The UK life sciences sector employs roughly 300,000 people and biotech vacancies grew an estimated 23.7% in a recent year, with bioinformatics and data science among the fastest-growing specialisms. Salaries for in-demand skills carry premiums. Employers including AstraZeneca, GSK and Oxford Nanopore are investing heavily in AI. The likeliest outcome for most biotech professionals is that AI becomes a tool within the role, not a substitute for it, though the pace of change is uncertain and varies by job.

Will AI Replace Biotechnology Jobs?

The fear of mass displacement is understandable, but the available evidence suggests a more nuanced story for biotech specifically. Broad UK labour studies do flag significant exposure. The Institute for Public Policy Research (IPPR) estimated in its 2024 analysis that up to 8 million UK jobs could be affected by AI over time, with administrative, secretarial and customer-service roles most exposed in the first wave. The PwC 2025 Global AI Jobs Barometer found that the skills employers ask for are changing around 25% faster in occupations most exposed to AI, which signals adaptation more than elimination.

Biotechnology roles tend to sit in a different category. Most scientific and laboratory jobs combine manual dexterity, judgement, regulatory accountability and hands-on troubleshooting, which are harder to automate end to end. The Office for National Statistics (ONS) reported that around 23% of UK businesses were using some form of AI by late September 2025, up three points from June, so adoption is real and accelerating, yet adoption in biotech has so far gone hand in hand with hiring for new technical specialisms rather than redundancy programmes. It would be unwise to claim any role is permanently safe, but the direction of travel for biotech is towards augmentation.

How Is AI Used in Drug Discovery?

AI is now embedded across the early drug discovery pipeline. Machine-learning models are used to predict how candidate molecules will bind to disease targets, to screen vast chemical libraries computationally before any compound is synthesised, and to prioritise which experiments are worth running in the wet lab. The aim is to compress the slow, expensive hit-to-lead phase and reduce the number of dead ends.

The UK has been a focal point for this approach. Oxford-founded Exscientia and US-based Recursion completed their merger in 2025, with a combined operation spanning Oxford and Salt Lake City, positioning themselves around the industrialisation of AI-led discovery. AstraZeneca, headquartered in Cambridge, has built substantial in-house data science and AI capability and in June 2025 entered an AI-powered oral drug discovery collaboration reported to involve an upfront payment of around 110 million US dollars with significant milestone potential. AstraZeneca and GSK have also jointly funded the Cambridge Centre for AI in Medicine alongside the University of Cambridge.

It is worth being measured about results. Several high-profile AI-derived candidates have been discontinued or out-licensed during 2025 and 2026, and the share prices of pure-play AI drug discovery firms have been volatile, reflecting realistic scepticism about near-term clinical payoff. The technology is reshaping how discovery is done; it has not yet rewritten the success rate of drug development.

Which Biotech Roles Are Growing in the UK?

Demand is concentrated where biology meets data and engineering. Bioinformatics and computational biology sit at the top of most employer wish lists, because AI models are only as useful as the people who can build, validate and interpret them. Roles in laboratory automation, assay development and AI or ML engineering applied to life sciences are also expanding, as are data management and quality roles that keep AI-ready datasets clean and compliant.

The sector backdrop supports continued hiring. The UK life sciences sector contributes on the order of £100,000 million to the economy and employs roughly 300,000 people. Long-term workforce projections cited by industry bodies point to a need for around 145,000 skilled workers over the coming decade, including roughly 70,000 newly created jobs by 2035. A Skills England assessment published in September 2024 warned of shortages across specialist science, digital and data skills, and medicines manufacturing, which tends to push salaries and competition for talent upwards rather than down.

Salary figures are indicative ranges drawn from 2025 to 2026 market sources such as Glassdoor and Indeed and from sector commentary, and they vary by location, employer and specialism.

How Is Lab Automation Changing Day-to-Day Biotech Work?

Automation is changing the texture of laboratory work as much as the headcount. Automated liquid handlers, robotic sample preparation and high-throughput screening platforms take on the repetitive, error-prone steps that once consumed large parts of a scientist's day. Long-read sequencing platforms from firms such as Oxford Nanopore, based near Oxford, generate data at volumes that simply cannot be handled by hand, which shifts effort towards pipeline design, quality control and interpretation.

In practice this means a research scientist in 2026 spends less time pipetting and more time designing experiments, reviewing automated output and asking whether the results make biological sense. The Wellcome Sanger Institute near Cambridge, one of the world's largest genomics centres, exemplifies how automation and informatics now sit at the core of the science rather than at its edge. For job seekers, familiarity with automated instrumentation, electronic lab notebooks and scripting is increasingly expected even in nominally bench-based roles. The skill that does not automate easily is judgement: knowing which question to ask and whether to trust the answer.

Which UK Employers and Locations Are Hiring?

The UK's biotech hiring map remains clustered, with the so-called golden triangle of Cambridge, Oxford and London dominating, plus the Stevenage cluster around the cell and gene therapy ecosystem. Named employers active in AI and automation-heavy work include AstraZeneca and GSK as the large-cap anchors, Oxford Nanopore for sequencing technology, Bicycle Therapeutics at Granta Park in Cambridge for novel chemistry-led discovery, the merged Recursion-Exscientia for AI-native platforms, and the Wellcome Sanger Institute for genomics at scale. BenevolentAI remains part of the UK AI drug discovery story, albeit through a more turbulent commercial period.

Funding has been a tailwind. UK biotech venture and follow-on funding reached around £3,500 million in a recent year, reported as nearly double the prior year, with a further substantial equity raise in early 2025. That capital tends to flow into therapeutics, diagnostics and deep-tech platforms that hire across both wet-lab and computational disciplines. Cambridge and Oxford carry premium demand and premium salaries; London concentrates senior scientific and commercial leadership; Stevenage and the wider South East add manufacturing and translational roles.

What Skills Should Biotech Professionals Build for 2026?

The most resilient profile blends domain biology with data fluency. Wet-lab scientists who can write basic Python or R, handle large datasets and interpret machine-learning output are markedly more employable than those who cannot, and the reverse is also true: data scientists who understand the underlying biology are far more useful than generic coders. Familiarity with laboratory automation platforms, electronic lab notebooks and reproducible computational pipelines is becoming a baseline expectation.

Regulatory literacy is rising in value too. The Medicines and Healthcare products Regulatory Agency (MHRA) ran a call for evidence on the regulation of AI in healthcare from December 2025 to February 2026 and is expected to publish a new framework during 2026, which means roles that combine science, AI and compliance are likely to be in demand. The BioIndustry Association (BIA) continues to highlight digital and data skills as a sector-wide gap. Practical steps for 2026 include learning the basics of AI tooling, building a portfolio that shows you can validate model output critically, and keeping current with how regulators expect AI to be used. None of this guarantees a role, but it improves the odds considerably.

Frequently Asked Questions: Biotechnology Jobs and AI

Are biotechnology jobs at risk from AI in the UK?

Broad studies such as the IPPR 2024 report flag wide exposure across the UK economy, but biotech roles tend to combine manual, regulated and judgement-based work that is harder to automate fully. The likeliest near-term outcome is that AI absorbs routine tasks within roles rather than removing whole jobs, though exposure varies and no role is entirely insulated.

Do I need to learn coding to work in biotech now?

Not always, but it increasingly helps. Many wet-lab roles still centre on bench skills, yet basic proficiency in Python or R, plus comfort handling large datasets, makes candidates more competitive. For bioinformatics and computational biology roles, strong programming and statistics are essential rather than optional in 2026.

Which biotech roles are growing fastest in the UK?

Bioinformatics, computational biology, lab automation engineering and AI or ML roles applied to life sciences are among the fastest-growing specialisms. Data management and quality roles supporting AI-ready datasets are also expanding. Sector projections point to roughly 70,000 newly created jobs by 2035, with digital and data skills repeatedly flagged as shortage areas.

How much do bioinformatics jobs pay in the UK?

Estimates vary by source and location. The average bioinformatician salary in England has been reported at around £53,000, with broader UK averages nearer £44,000 and top earners around £67,000 or more in 2025 to 2026 data. Cambridge, Oxford and London typically pay above national averages for these roles.

Is AI drug discovery actually working?

It is changing how early discovery is done by screening molecules computationally and prioritising experiments. Results so far are mixed: several AI-derived candidates were discontinued during 2025 and 2026, and investor sentiment has been cautious. The technology appears to be improving efficiency in parts of the pipeline rather than transforming overall drug-development success rates.

Which UK companies use AI in drug discovery?

Named examples include AstraZeneca and GSK among large employers, the merged Recursion-Exscientia as an AI-native platform, Oxford Nanopore in sequencing, Bicycle Therapeutics in Cambridge and the Wellcome Sanger Institute in genomics. BenevolentAI is also part of the UK landscape. Most are clustered around Cambridge, Oxford, London and Stevenage.

Will lab automation reduce the number of scientists employed?

Automation reduces time spent on repetitive tasks but has so far gone alongside hiring for new technical specialisms in the UK. The role of the scientist is shifting towards experiment design, oversight and interpretation. It is plausible that some routine sampling tasks shrink, while demand for skilled judgement and automation expertise grows.

Summary: Biotechnology Jobs and AI in 2026

AI-driven drug discovery and lab automation are genuinely reshaping biotechnology jobs in the UK, but the evidence points to roles being redesigned rather than swept away. Demand is strongest where biology meets data, with bioinformatics, computational biology and lab automation among the clearest growth areas, supported by significant funding and a sector employing around 300,000 people. Major employers including AstraZeneca, GSK, Oxford Nanopore and the merged Recursion-Exscientia continue to invest, while regulators such as the MHRA work on a 2026 AI framework. The most resilient biotech professionals will be those who pair scientific depth with data fluency and a critical eye for AI output, though the pace and shape of change remain uncertain.

Ready to take the next step in your biotech career? Browse the latest AI, bioinformatics and laboratory roles at biotechnologyjobs.co.uk.